



2024

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Speech Abstract

Topic:

From Consistent 1L CDK4/6i Evidence Based Survival Benefit to Real World Clinical Practice in HR+HER2 mBC

Abstract

In recent years, the use of CDK4/6 inhibitors (CDK4/6i) has become a cornerstone in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer (HR+HER2 mBC). Clinical trials have demonstrated significant survival benefits associated with these agents, leading to their widespread adoption in oncology practice.

We will review data from Asian RWE to Taiwan local real world cases series, highlighting the robust survival benefits and improved progression-free survival (PFS) associated with CDK4/6i therapy in combination with aromatase inhibitors.

CDK4/6i has been reimbursed for couple years and even expanded to pre-menopausal patients in 2024. It has been a long await good news and benefits to follow international guideline locally.

Patients suffered from getting chemo before the enrollment.

In real world practice, we have 2-year capping for reimbursement, facing different challenges and dealing with more sequencing issue at the same time.

As CDK4/6i launched, we already have various of patient type and modify by time to time. By bridging the gap between controlled trial environments and diverse patient populations, this paper aims to provide a comprehensive understanding of how CDK4/6i therapy can be optimized to enhance patient care in HR+HER2 mBC, ensuring that clinical benefits observed in trials translate effectively into everyday practice.